Kura Oncology Reports Third Quarter 2018 Financial Results and Provides Corporate Update
05 nov. 2018 16h05 HE
|
Kura Oncology, Inc.
– Registration-directed trial of tipifarnib in HRAS mutant HNSCC now underway – – Encouraging preliminary clinical activity observed in HRAS mutant SCC cohort – – Preliminary data from AITL and...
Kura Oncology Initiates Registration-Directed Trial of Tipifarnib in HRAS Mutant Head and Neck Squamous Cell Carcinomas
05 nov. 2018 07h30 HE
|
Kura Oncology, Inc.
– AIM-HN designed to enroll at least 59 patients with HRAS mutant HNSCC – – Full enrollment expected in two years with response rate as primary endpoint – SAN DIEGO, Nov. 05, 2018 (GLOBE NEWSWIRE)...
Kura Oncology Announces Upcoming Presentations at ASH Annual Meeting
01 nov. 2018 09h00 HE
|
Kura Oncology, Inc.
SAN DIEGO, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Presents Update on Positive Phase 2 Trial of Tipifarnib in HRAS Mutant HNSCC and Preliminary Results in HRAS Mutant SCC
22 oct. 2018 08h45 HE
|
Kura Oncology, Inc.
– Nine patients with HRAS mutant HNSCC experienced tumor size reductions, including six confirmed PRs and two patients with disease stabilization greater than six months – – One additional HNSCC...
Kura Oncology to Present at Leerink Partners Rare Disease & Oncology Roundtable
26 sept. 2018 16h05 HE
|
Kura Oncology, Inc.
SAN DIEGO, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...